Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25527631 | 0.69 | PLAU (0.54) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL18773359 | 0.65 | PLAU (0.52) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL25528016 | 0.64 | IDO1 (0.39) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL18480045 | 0.61 | PLAU (0.59) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL11839172 | 0.58 | PLAU (0.54) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL21938896 | 0.58 | PLAU (0.48) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL7062605 | 0.58 | PLAU (0.43) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL8368541 | 0.57 | CYP19A1 (0.43) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL15653055 | 0.57 | PLAU (0.52) | PLAUMASP2THPOF2PRSS1 | |
| SCHEMBL42732 | 0.57 | CA1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020127685-A1 | AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2020-06-25 | — | — | WO | disclosed |